Pietrapertosa A, Palma A, Campanale D, Delios G, Vitucci A, Tannoia N
Chair of Hematology II, University of Bari, Italy.
Haematologica. 2001 Jan;86(1):30-5.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common erythrocytic enzymatic disorder in Italy and is characterized by wide clinical, biochemical and molecular variability. We studied the clinical and hematologic data from 54 G6PD-deficient, unrelated males from the Apulia region.
Analyses for enzymatic activity, G6PD electrophoresis and molecular typing were performed on all subjects. Thirty-nine subjects (72.2%) showed a severe G6PD deficiency (<10% residual enzymatic activity) and 15 subjects (27.8%) a moderate deficiency (10--60% residual activity).
The Mediterranean variant was found in 48.2% of cases, the Seattle variant in 33.3%, the A- variant in 7.45% and the Montalbano variant in 3.7%; the variant was not identified in four subjects. Thirty-two patients (59.2%) were asymptomatic; of these, 37.04% demonstrated acute hemolytic crises induced mainly by ingestion of fava beans and 3.7% had had neonatal jaundice. Acute hemolytic anemia was found in 53.8% of subjects with the Mediterranean variant, in 5.5% with the Seattle variant, in 100% with the A-variant and 0% with the Montalbano variant.
Enzymatic activity was shown to be a poor predictive parameter of acute hemolytic crises and was not correlated with clinical features. Subjects with Mediterranean or A- variants had a more severe clinical phenotype which was not related to enzymatic activity. The Seattle, and probably the Montalbano, variant appears to have a milder clinical expression.
葡萄糖-6-磷酸脱氢酶(G6PD)缺乏症是意大利最常见的红细胞酶病,其临床、生化及分子特征具有高度变异性。我们研究了来自普利亚地区的54名非亲属G6PD缺乏男性的临床和血液学数据。
对所有受试者进行酶活性分析、G6PD电泳及分子分型。39名受试者(72.2%)表现为严重G6PD缺乏(残余酶活性<10%),15名受试者(27.8%)表现为中度缺乏(残余活性为10% - 60%)。
48.2%的病例发现为地中海型变异,33.3%为西雅图型变异,7.45%为A - 型变异,3.7%为蒙塔尔巴诺型变异;4名受试者未鉴定出变异型。32名患者(59.2%)无症状;其中,37.04%曾因主要摄入蚕豆引发急性溶血危机,3.7%曾患新生儿黄疸。地中海型变异的受试者中53.8%出现急性溶血性贫血,西雅图型变异者中为5.5%,A - 型变异者中为100%,蒙塔尔巴诺型变异者中为0%。
酶活性被证明是急性溶血危机的不良预测参数,且与临床特征无关。地中海型或A - 型变异的受试者临床表型更严重,这与酶活性无关。西雅图型,可能还有蒙塔尔巴诺型变异,似乎具有较温和的临床表型。